about
An old enzyme for current needs: adenosine deaminase and a dendritic cell vaccine for HIV.Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progressionHuman CD6 Down-Modulation following T-Cell Activation Compromises Lymphocyte Survival and Proliferative Responses.CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse.Genetic characterization of the Klebsiella pneumoniae waa gene cluster, involved in core lipopolysaccharide biosynthesisAdenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIV-infected individuals.A therapeutic dendritic cell-based vaccine for HIV-1 infection.A gene (wbbL) from Serratia marcescens N28b (O4) complements the rfb-50 mutation of Escherichia coli K-12 derivatives.Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.Impact of long-term antiretroviral therapy interruption and resumption on viral reservoir in HIV-1 infected patients.Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells.Assessment of migration of HIV-1-loaded dendritic cells labeled with 111In-oxine used as a therapeutic vaccine in HIV-1-infected patients.Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands.Increased expression with differential subcellular location of cytidine deaminase APOBEC3G in human CD4(+) T-cell activation and dendritic cell maturation.Adenosine deaminase regulates Treg expression in autologous T cell-dendritic cell cocultures from patients infected with HIV-1.Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses.Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDSImmunological dysfunction in HIV-1-infected individuals caused by impairment of adenosine deaminase-induced costimulation of T-cell activation.Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV.Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells.P10-13. Increased production of alpha-defensins 1–3 by dendritic cells in HIV-infected individuals is associated with a slower disease progression rate.Impact of alpha-defensins1-3 on the maturation and differentiation of human monocyte-derived DCs. Concentration-dependent opposite dual effects.P18-07. Ex vivo production of autologous HIV-1 to be used as immunogen in autologous dendritic cell-based therapeutic vaccine (clinical trial DCV02).Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccinesP20-06. Study of viral variability evolution in patients submitted to a therapeutic vaccine based on autologous dendritic cells pulsed with autologous HIV-1Therapeutic Immunization with Dendritic Cells Loaded with Heat‐Inactivated Autologous HIV‐1 in Patients with Chronic HIV‐1 InfectionExpression and function of the IL-2 receptor in activated human plasmacytoid dendritic cellsTacrolimus treatment of plasmacytoid dendritic cells inhibits dinucleotide (CpG-)-induced tumour necrosis factor-alpha secretionHuman immature monocyte-derived dendritic cells produce and secrete α-defensins 1-3HIV-1 upregulates intercellular adhesion molecule-1 gene expression in lymphoid tissue of patients with chronic HIV-1 infection
P50
Q30407263-53D6B48B-A049-4D9C-B1CC-2A19E3407835Q33535953-C37E2AD3-0A5B-46E8-89D6-F31325B6F6F9Q33857839-8D35501E-3A63-4F3F-8D78-A9B8EF3B4753Q33892260-5716E950-D01A-4FE0-A0D6-457981264BFDQ33996257-E3C53802-77BD-41ED-BE0E-84249E5D0C87Q34512293-FAB46C53-3A93-4742-8137-78DE2DF523FBQ34764392-62912557-E485-4840-97F6-92870526BF75Q35634004-A5205EB9-A066-4EBD-AC0B-50E1929BC7A9Q35947683-A5B67524-8E96-4BA9-8514-88476161B798Q38296086-F39E59E9-82B5-43D1-938C-4AEED6B76AB2Q38738697-D832D749-A757-4166-B978-CB23B50D9418Q38911430-E6D90035-48A2-4771-9DFC-18B0A7DFF806Q39984018-AC2EC53C-D84E-4C97-BFB4-1AB8D95E553BQ40353193-D6B74F44-5B41-4415-B27E-B36C78995176Q40751332-722F0702-6CC0-4DE0-84F4-7D66201BA48FQ41031764-D496F71C-A5F0-4646-9C45-435217923890Q41731948-AFA27C70-3D32-4114-989E-ADBD81DD2805Q42575428-2EE546F8-99BB-4813-BB40-F962C007A27CQ43196418-E40A5246-BDD2-4D87-8705-93E174EE2DB5Q43294881-B78BDD93-7B67-4A33-9646-E27D42553568Q43840575-5D6917C2-9E43-4BBC-AEDB-DB5F676703D8Q45752704-07126B52-7C02-478F-B593-C1BB3D767A5BQ51804196-A8AF6EBA-BF6F-4501-BB00-A6699B35C271Q55488579-47FF11D1-4EC5-47FD-A382-D4D4E01CDC3BQ56791508-12F89E89-CE66-4613-862B-3F50A372E6B8Q56791522-B7F3C52C-DE31-47D5-9E30-8BA6D61EB124Q56791539-66846F59-DFBE-4A2F-980C-627CE4CA04BFQ61656628-8BB9ABC5-1936-442A-BB64-5CC9B5AB9601Q61656632-97565892-8D4D-4D7C-963A-F6F8BD7A7928Q61767217-89B134C9-EA9D-4CC2-9E36-A0FA9FCAB2E2Q81040406-37DCA488-A68C-49D4-BDC8-2AB9403D83D6
P50
description
Spaans onderzoekster
@nl
hulumtuese
@sq
researcher
@en
spanische Forscherin
@de
taighdeoir
@ga
հետազոտող
@hy
name
Núria Climent
@ast
Núria Climent
@en
Núria Climent
@es
Núria Climent
@ga
Núria Climent
@nl
Núria Climent
@sl
type
label
Núria Climent
@ast
Núria Climent
@en
Núria Climent
@es
Núria Climent
@ga
Núria Climent
@nl
Núria Climent
@sl
prefLabel
Núria Climent
@ast
Núria Climent
@en
Núria Climent
@es
Núria Climent
@ga
Núria Climent
@nl
Núria Climent
@sl
P106
P1153
8566781100
P21
P27
P31
P496
0000-0002-0791-656X